• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三例 COVID-19 肺炎老年患者需要氧疗时使用那屈肝素的治疗案例。

Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.

机构信息

Division of Infectious Diseases, Department of Medicine, Dankook University Hospital, Dankook University College of Medicine, 201 Manghang-ro, Dongnam-ku, Chungcheongnam-do, South Korea.

Division of Infectious Diseases, Department of Medicine, Dankook University Hospital, Dankook University College of Medicine, 201 Manghang-ro, Dongnam-ku, Chungcheongnam-do, South Korea.

出版信息

Int J Infect Dis. 2020 Jul;96:500-502. doi: 10.1016/j.ijid.2020.05.072. Epub 2020 May 26.

DOI:10.1016/j.ijid.2020.05.072
PMID:32470602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7250091/
Abstract

No effective treatment for COVID-19 has been well established yet. Nafamostat, known as anticoagulant, has potential anti-inflammatory and anti-viral activities against COVID-19. We report three cases of COVID-19 pneumonia who progressed while using antiviral drugs and needed supplementary oxygen therapy, improved after treatment with nafamostat. These preliminary findings show the possibility that Nafamostat can be considered to be used in elderly patients with COVID-19 pneumonia who need oxygen therapy. The effectiveness of nafamostat should be evaluated in further studies.

摘要

目前尚未确立针对 COVID-19 的有效治疗方法。那屈肝素作为一种抗凝剂，具有针对 COVID-19 的潜在抗炎和抗病毒活性。我们报告了三例 COVID-19 肺炎患者，他们在使用抗病毒药物时病情进展，需要补充氧疗，经那屈肝素治疗后得到改善。这些初步发现表明，那屈肝素可考虑用于需要氧疗的 COVID-19 肺炎老年患者。需要进一步研究评估那屈肝素的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fee/7250091/9f5a690fc382/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fee/7250091/9f5a690fc382/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fee/7250091/9f5a690fc382/gr1_lrg.jpg

相似文献

1
Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.三例 COVID-19 肺炎老年患者需要氧疗时使用那屈肝素的治疗案例。
Int J Infect Dis. 2020 Jul;96:500-502. doi: 10.1016/j.ijid.2020.05.072. Epub 2020 May 26.
2
Partially ionized medical oxygen as a supplementary treatment for COVID-19.部分电离医用氧气作为新型冠状病毒肺炎的辅助治疗手段
Wien Klin Wochenschr. 2020 Nov;132(21-22):697-698. doi: 10.1007/s00508-020-01717-7. Epub 2020 Jul 30.
3
Nocturnal oxygen therapy as an option for early COVID-19.夜间氧疗作为早期新型冠状病毒肺炎的一种治疗选择。
Int J Infect Dis. 2020 Sep;98:176-179. doi: 10.1016/j.ijid.2020.06.080. Epub 2020 Jun 26.
4
Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19.氧-臭氧（O2-O3）疗法有助于治疗新型冠状病毒COVID-19的潜在机制。
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4059-4061. doi: 10.26355/eurrev_202004_20976.
5
[Airborne spread of coronavirus in critical coronavirus disease 2019 patients with different oxygen therapies].[2019年冠状病毒病重症患者不同氧疗方式下冠状病毒的空气传播]
Zhonghua Nei Ke Za Zhi. 2020 Sep 1;59(9):664-666. doi: 10.3760/cma.j.cn112138-20200318-00254.
6
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.羟氯喹联合甲磺酸萘莫司他连续性血液透析滤过治疗重症 COVID-19 患者的临床疗效。
J Infect Chemother. 2020 Dec;26(12):1319-1323. doi: 10.1016/j.jiac.2020.08.001. Epub 2020 Aug 6.
7
Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.臭氧氧气疗法作为 SARS-CoV-2 感染急救治疗的辅助手段：一项临床研究。
J Biol Regul Homeost Agents. 2020 May-Jun;34(3):757-766. doi: 10.23812/20-250-E-56.
8
Oxygen provision to fight COVID-19 in sub-Saharan Africa.在撒哈拉以南非洲地区提供氧气以抗击新冠疫情。
BMJ Glob Health. 2020 Jun;5(6). doi: 10.1136/bmjgh-2020-002786.
9
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.蛋白酶抑制剂：抑制严重急性呼吸综合征冠状病毒 2 复制的候选药物。
Tohoku J Exp Med. 2020 May;251(1):27-30. doi: 10.1620/tjem.251.27.
10
Potential Role of Oxygen-Ozone Therapy in Treatment of COVID-19 Pneumonia.氧-臭氧疗法在新冠肺炎治疗中的潜在作用
Am J Case Rep. 2020 Aug 17;21:e925849. doi: 10.12659/AJCR.925849.

引用本文的文献

1
Elucidation of the mechanism of precipitate formation on mixing nafamostat mesylate solution with dialysate.甲磺酸萘莫司他溶液与透析液混合时沉淀形成机制的阐明。
J Artif Organs. 2025 Apr 8. doi: 10.1007/s10047-025-01500-3.
2
Emerging patterns of hypercoagulability associated with critical COVID-19: A review.与重症新型冠状病毒肺炎相关的高凝状态新趋势：综述
Trends Anaesth Crit Care. 2020 Oct;34:4-13. doi: 10.1016/j.tacc.2020.07.004. Epub 2020 Jul 9.
3
Multisite spontaneous hematomas and bleeding in critically ill Chinese patients with COVID-19: two case reports and a literature review.

本文引用的文献

1
Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action.新型冠状病毒肺炎患者的血栓栓塞风险和抗凝治疗：新出现的证据和行动呼吁。
Br J Haematol. 2020 Jun;189(5):846-847. doi: 10.1111/bjh.16727. Epub 2020 May 4.
2
Virology, Epidemiology, Pathogenesis, and Control of COVID-19.COVID-19 的病毒学、流行病学、发病机制和防控。
Viruses. 2020 Mar 27;12(4):372. doi: 10.3390/v12040372.
3
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
多部位自发性血肿和出血：COVID-19 危重症中国患者的两例病例报告和文献复习。
BMC Infect Dis. 2024 Jan 18;24(1):101. doi: 10.1186/s12879-024-09012-w.
4
Global research trends related to coronavirus disease 2019 and the aged: a bibliometric analysis.全球与 2019 年冠状病毒病和老年人相关的研究趋势：文献计量分析。
Sao Paulo Med J. 2023 Aug 4;142(2):e2022662. doi: 10.1590/1516-3180.2022.0662.R1.190523. eCollection 2023.
5
Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors.李斯特菌 HtrA 蛋白酶的抑制作用：卡梅替丁、加贝酯和甲磺酸萘莫司他及其抑制剂的结合模式。
Protein J. 2023 Aug;42(4):343-354. doi: 10.1007/s10930-023-10114-8. Epub 2023 Apr 24.
6
Interaction of copper potential metallodrugs with TMPRSS2: A comparative study of docking tools and its implications on COVID-19.铜潜在金属药物与跨膜丝氨酸蛋白酶2的相互作用：对接工具的比较研究及其对COVID-19的影响
Front Chem. 2023 Jan 26;11:1128859. doi: 10.3389/fchem.2023.1128859. eCollection 2023.
7
Predicting the systemic exposure and lung concentration of nafamostat using physiologically-based pharmacokinetic modeling.使用基于生理的药代动力学模型预测那法莫司他的全身暴露量和肺部浓度。
Transl Clin Pharmacol. 2022 Dec;30(4):201-211. doi: 10.12793/tcp.2022.30.e20. Epub 2022 Dec 21.
8
Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients.在 COVID-19 患者中使用抗雄激素作为治疗药物。
Viruses. 2022 Dec 7;14(12):2728. doi: 10.3390/v14122728.
9
ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial.ASCOT ADAPT 研究：COVID-19 治疗药物在住院患者中的应用：一项国际性多中心适应性平台试验。
Trials. 2022 Dec 14;23(1):1014. doi: 10.1186/s13063-022-06929-y.
10
Druggable targets and therapeutic development for COVID-19.2019冠状病毒病的可药物化靶点与治疗开发
Front Chem. 2022 Oct 5;10:963701. doi: 10.3389/fchem.2022.963701. eCollection 2022.
2019 冠状病毒病（COVID-19）疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
4
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
5
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
6
Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.使用基于分裂蛋白的细胞-细胞融合试验鉴定那法莫司他为中东呼吸综合征冠状病毒S蛋白介导的膜融合的有效抑制剂。
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539. doi: 10.1128/AAC.01043-16. Print 2016 Nov.